Cambridge Cognition Holdings Plc (LON:COG) CEO Dr. Steven Powell talks to DirectorsTalk about its half year report. Steven talks us through the results, explains why the sales mix has changed, why the company appears to be second half weighted, the significance of a recent £300k grant and the outlook for the rest of the year and into 2018.
Dr Powell graduated in microbiology from the University of Wales and was awarded a PhD from the University of Aberdeen. He has over thirty years operational and investment experience in pharmaceutical and healthcare companies in the UK, USA and Scandinavia. Including his current role at Cambridge Cognition, he has held five CEO roles, three in public companies. In 2003, he joined Gilde Healthcare, a pan-European life sciences investment fund as a partner and remained an adviser to the fund until 2016.
Cambridge Cognition Holdings Plc is a neuroscience digital health company developing products to better understand, detect and treat brain health conditions. The company’s cognitive technologies accelerate research and development of new treatments, enhance understanding of the brain and measure cognitive health in patients worldwide.